Sentrimed
Company Details
Status: Private
Employees: 1-10
Location:
Mullica Hill, New Jersey, United States
Type:
sample
Technology:
sample
About: Sentrimed is a clinical stage biotechnology company developing novel targeted therapies that harness cell-to-cell communication pathways essential to reviving the body's ability to recognize, immobilize and eliminate tumor cells. Sentrimed is a leader in contact normalization, a cellular communication process that enables normal cells to inhibit tumor proliferation and migration, and trigger tumor cell destruction.
Tumor cell motility and survival are core issues in cancer impacting proliferation, migration, metastasis and overall patient prognosis. When mutagenesis occurs and normal cells are transformed into tumor cells, podoplanin (PDPN) is induced, disrupting normal cell-to-cell communication, and allowing tumor cells to escape contact normalization, proliferate and migrate. PDPN, a transmembrane glycoprotein receptor that is an early expressed tumor biomarker, is overexpressed in many cancers and is correlated with poor outcomes.
Our lead product, MASL®, is a novel, orally dosed, bioactive lectin. MASL potently inhibits PDPN and blocks PDPN mediated activation of Cdc42 and downstream signaling important to cancer progression. MASL revives contact normalization to inhibit tumor cell proliferation and migration, and triggers destruction. MASL has demonstrated both cytostatic and cytotoxic effects on drug resistant human oral squamous cell carcinoma (OSCC) cells. Animal studies have not produced any identifiable adverse effects. The first indication we will seek is Head and Neck Cancers (HNC) which is a rapidly growing market with significant unmet needs.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Sentrimed | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.